The role of SGLT2 inhibitors in reducing cardiovascular events attributable to atherosclerotic cardiovascular disease (ASCVD), however, has been questioned, due to inconclusive results with respect to myocardial infarction (MI) and stroke outcomes. The gene discussed is SLC5A2; the disease is atherosclerosis.